Marsala Biotech Inc.
Marsala Biotech is developing endostatin gene therapy for the treatment of cancer a huge unmet therapeutic need and commercial opportunity.
Marsala Biotech Inc.'s lead technology E10A, is being evaluated in head and neck cancer patients. Currently there are only 2 FDA approved drugs which have significant drawbacks. Pre-clinical and Phase-I and II clinical trials are complete and a Phase-III clinical trial was initiated in Oct 2013 by Marsala's JV partner in China. Marsala has obtained a SPA from the USFDA and clinical trials are planned for Q1 2016 in Europe and North America.